This is a phase III clinical trial using risk-adapted therapy. Treatment outcomes for
children with B-cell NHL are excellent. Further improvements in outcome will likely be
achieved through more focused study of the biology of the tumors and prospective studies of
the late effects of treatment. Toward this end, this study features a spectrum of prospective
biologic and late effect studies performed in patients treated with a modified regimen
derived from the very successful LMB-96 regimen.